Our Focus

The Colorado Chapter of the National Bleeding Disorders Foundation (NBDF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.

El Capítulo de Colorado de la Fundación Nacional de Trastornos Hemorrágicos (NBDF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. 


News Articles

The National Bleeding Disorders Foundation (NBDF) is delighted to announce a new accredited education opportunity for health care providers focused on personalized care for individuals with von Willebrand disease (VWD).

“Restoring Control in von Willebrand Disease: Collaborative Approaches for Delivering the Right Treatment for the Right Patient at the Right Time,” is an enduring activity planned and implemented by the PeerView Institute (PVI) for Medical Education and NBDF. 

The U.S. Food and Drug Administration (FDA) has approved the ConcizuTrace™ ELISA Companion Diagnostic (CDx) test, which helps to determine the amount of concizumab-mtci that is circulating in an individual who has taken the product.

In a May 27th letter to the hemophilia community, it was confirmed that Spark Therapeutics has been fully integrated into the Roche Group. Spark first became a member of the Roche Group in 2019 with the aim of continuing to advance potential gene therapies for hemophilia and many other genetic diseases.

OUR ADVERTISERS


13199 E Montview Blvd
STE 200
Aurora, CO 80045

© National Bleeding Disorders Foundation 2025

Crafted by Firespring